Medical Management of Drug-Resistant Tuberculosis.
10.4046/trd.2015.78.3.168
- Author:
Doosoo JEON
1
Author Information
1. Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea. sooli10kr@yahoo.co.kr
- Publication Type:Meta-Analysis ; Review
- Keywords:
Tuberculosis;
Drug Resistance;
Tuberculosis, Multidrug-Resistant;
Extensively Drug-Resistant Tuberculosis
- MeSH:
Drug Resistance;
Extensively Drug-Resistant Tuberculosis;
Humans;
Methods;
Tuberculosis;
Tuberculosis, Multidrug-Resistant*;
World Health Organization
- From:Tuberculosis and Respiratory Diseases
2015;78(3):168-174
- CountryRepublic of Korea
- Language:English
-
Abstract:
Drug-resistant tuberculosis (TB) is still a major threat worldwide. However, recent scientific advances in diagnostic and therapeutic tools have improved the management of drug-resistant TB. The development of rapid molecular testing methods allows for the early detection of drug resistance and prompt initiation of an appropriate treatment. In addition, there has been growing supportive evidence for shorter treatment regimens in multidrug-resistant TB; and for the first time in over 50 years, new anti-TB drugs have been developed. The World Health Organization has recently revised their guidelines, primarily based on evidence from a meta-analysis of individual patient data (n=9,153) derived from 32 observational studies, and outlined the recommended combination and correct use of available anti-TB drugs. This review summarizes the updated guidelines with a focus on the medical management of drug-resistant TB.
